Breakthrough Oral Medication Slashes Bad Cholesterol by 60 Percent

A major shift in cardiovascular medicine is on the horizon as Merck’s experimental drug, enlicitide, has demonstrated a remarkable ability to lower low-density lipoprotein (LDL) cholesterol by up to 60 percent. This breakthrough represents a significant leap forward in lipid-management therapy, offering a potent alternative for patients who have previously struggled to reach their health targets through traditional means.

The development of enlicitide marks the first time an oral tablet has matched the high efficacy levels previously only seen in injectable medications known as PCSK9 inhibitors. For millions of people worldwide, this transition from a syringe to a daily pill could simplify treatment regimens and improve long-term adherence to life-saving cholesterol protocols.

The clinical evidence supporting this new treatment comes from the extensive Phase III CORALreef Lipids trial. This massive international effort involved more than 2900 participants across 14 different countries, providing a robust dataset that underscores the drug's potential impact on global public health and its reliability across diverse patient populations.

Safety remains a paramount concern in the development of any new pharmaceutical, and enlicitide has shown promising results in this area. The study revealed that the drug's side-effect profile is essentially comparable to that of a placebo, with no serious complications or adverse events identified during the rigorous testing phases.

Detailed findings from this landmark Phase III study were published in the prestigious New England Journal of Medicine in February 2026. The data confirmed that the era of relying solely on painful injections to manage hypercholesterolemia might be nearing its conclusion, as enlicitide achieved LDL reductions ranging from 55.8 to 60 percent—a feat once reserved for expensive monoclonal antibody treatments.

The biological mechanism behind enlicitide is both elegant and effective. As an oral PCSK9 inhibitor, the drug targets a specific protein that normally binds to LDL receptors on the liver's surface, leading to their degradation. By blocking this protein, enlicitide increases the density of these receptors, allowing the liver to more efficiently capture and remove harmful cholesterol from the bloodstream.

Dr. Ann Marie Navar, a prominent cardiologist at the UT Southwestern Medical Center and the study's lead author, emphasized the clinical necessity of such a breakthrough. She noted that fewer than half of all patients diagnosed with atherosclerosis manage to reach their target cholesterol levels using standard statin therapy alone. According to Dr. Navar, an oral treatment with this level of potency could fundamentally transform the landscape of preventative care, potentially averting thousands of heart attacks and strokes.

Despite the overwhelming success of the trials, there are specific administration requirements that patients must follow. To ensure maximum absorption, enlicitide must be taken strictly on an empty stomach, specifically at least 30 minutes before eating breakfast, as the presence of food has been shown to significantly diminish the drug's bioavailability.

Looking ahead, the scientific community is eagerly awaiting the results of the ongoing CORALreef Outcomes study. This follow-up research aims to prove that the impressive numerical reductions in cholesterol levels translate directly into a decrease in cardiovascular mortality rates. While final data from this phase are not expected until 2029, Merck is already moving forward with the necessary documentation for accelerated FDA registration.

• Enlicitide represents a revolution in lipid therapy, achieving a 60 percent reduction in "bad" cholesterol.
• This medication serves as the first oral alternative to high-potency injectable PCSK9 inhibitors.
• The Phase III CORALreef Lipids study included 2900 patients across 14 nations.
• Safety data indicates a profile similar to placebo with no major complications reported.